secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2026-07-30T11:38:04+00:00
Accession:  0001193125-26-324917
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences Q2 net loss $69.4M; WVE-007 Phase 2a dosing underway; FDA meeting for WVE-006
--------------------------------------------------------------------------------

- Net loss $69.4M vs $50.5M YoY; revenue $2.3M vs $8.7M; cash $490.6M, runway into 3Q 2028.
- WVE-007 (obesity) Phase 2a multidose dosing underway in BMI 35-50; combo/maintenance trials on track for 2H 2026.
- FDA meeting scheduled for end of summer 2026 to discuss accelerated approval for WVE-006 (AATD).
- WVE-008 (PNPLA3) CTA filing on track for 2H 2026; partnering discussions for HD and DMD programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526324917/0001193125-26-324917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526324917/d177737d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-324917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer